NYXH VS IMAB Stock Comparison

Performance

NYXH
10/100

NYXH returned -15.83% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

IMAB
10/100

IMAB returned -64.21% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Technicals

NYXH
14/100

NYXH receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

IMAB
64/100

IMAB receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

Earnings

NYXH
10/100

NYXH has missed earnings 5 times in the last 20 quarters.

IMAB
100/100

IMAB has missed earnings 0 times in the last 20 quarters.

Profit

NYXH
10/100

Out of the last 13 quarters, NYXH has had 0 profitable quarters and has increased their profits year over year on 0 of them.

IMAB
30/100

Out of the last 9 quarters, IMAB has had 2 profitable quarters and has increased their profits year over year on 2 of them.

Volatility

NYXH
45/100

NYXH has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.

IMAB
47/100

IMAB has had a lower than average amount of volatility over the last 12 months giving it a score of 46 of 100.

Sentiment

NYXH

"Sentiment" not found for NYXH

IMAB
67/100

IMAB had a bullish sentiment score of 67.16% across Twitter and StockTwits over the last 12 months. It had an average of 5.30 posts, 4.42 comments, and 5.75 likes per day.

All score calculations are broken down here to help you make more informed investing decisions

Nyxoah SA Ordinary Shares Summary

Nasdaq / NYXH

Healthcare

Medical - Instruments & Supplies

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

I-MAB American Depositary Shares Summary

Nasdaq / IMAB

Healthcare

Biotechnology

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

Power up your portfolio